Rheumatologists and pulmonologists provide differing perspectives on risk factors, disease assessment, and treatment strategies for patients with rheumatoid arthritis-associated interstitial lung disease.
Do gastroprotective and promotility agents prevent incident interstitial lung disease in patients with systemic sclerosis?
Researchers assessed mortality rates in rheumatoid arthritis-related interstitial lung disease as well as the association between mortality, radiographic patterns, and confounding factors.
Toby Maher, MD, describes the increased prevalence of lung manifestations in scleroderma and the need for routine screening among these patients.
Researchers evaluated the association between rheumatoid arthritis and the type and severity of pulmonary patterns on spirometry.
Although the overall rheumatoid arthritis-related mortality rates have been decreasing in recent years, rates of mortality among patients with rheumatoid arthritis-associated interstitial lung disease remain stable.
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.
Researchers evaluated the clinical characteristics and risk factors of acute exacerbations and mortality of rheumatoid arthritis-associated interstitial lung disease.
Study authors analyzed the effects of nintedanib on changes in forced vital capacity and other measures of progression in systemic sclerosis-associated interstitial lung disease.
